Skip Navigation
Search Menu
Find an Expert

 


Emmanuel Stylianos Antonarakis, M.B.B.Ch.

Photo of Dr. Emmanuel Stylianos Antonarakis, M.B.B.Ch.

Associate Professor of Oncology

Male

Languages: English, French, Greek

Expertise: Bladder Cancer, Kidney Cancer, Medical Oncology, Prostate Cancer, Testicular Cancer, Urological Oncology, Urology

Research Interests: Prostate cancer clinical trials; Prostate cancer biomarker development; AR-V7 biomarker; Androgen receptor-targeted therapy; Immunotherapy

Request an Appointment

I live in Maryland

410-955-8964
Request an appointment through MyChart!

I live outside of Maryland

410-464-6641
Request Appointment

I live outside of the United States

+1-410-502-7683
Request Appointment

Locations

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Appointment Phone: 410-955-8964

401 N. Broadway
Baltimore, MD 21231 map
Phone: 410-502-3823
Fax: 410-502-1419

Background

Dr Antonarakis is an Associate Professor of Oncology and Urology at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center. He obtained his medical degree from the University of Wales College of Medicine (United Kingdom) in 2003, and then completed a Residency in Internal Medicine at the Johns Hopkins Bayview Medical Center, followed by a Fellowship in Medical Oncology at the Johns Hopkins Hospital. In 2010, he joined the Johns Hopkins faculty as an attending physician and translational researcher. Dr Antonarakis’ clinical interest is the management of prostate cancer and other genitourinary malignancies (cancers of the bladder, kidney and testis).

His research focuses on drug development and clinical trial design for patients with prostate cancer. More specifically, he is interested in developing novel androgen-directed therapies as well as immunotherapies for men with recurrent or advanced prostate cancer. He also has an interest in biomarker development, specifically the clinical validation of the AR-V7 biomarker. He is currently the PI of several phase II and III prostate cancer trials, and is an active member of the Prostate Cancer Clinical Trials Consortium (PCCTC) and the Eastern Cooperative Oncology Group (ECOG) as well as the NCI Prostate Cancer Task Force. He serves on the Editorial Board of several oncology journals, including the Journal of Clinical Oncology. He is the author of over 110 peer-reviewed articles, and several book chapters.

 

...read more

Titles

  • Associate Professor of Oncology
  • Associate Professor of Urology

Departments / Divisions

Education

Degrees

  • MBBCh, University of Wales (2003)

Residencies

  • Johns Hopkins Bayview Medical Center / Internal Medicine (2007)

Fellowships

  • Johns Hopkins University School of Medicine / Oncology (2010)

Board Certifications

  • American Board of Internal Medicine / Internal Medicine (2007)
  • American Board of Internal Medicine / Medical Oncology (2009)

Additional Training

  • Physician License, State of Maryland (2007)

Research & Publications

Research Summary

Dr. Antonarakis is an Associate Professor of Oncology and Urology with an interest in genitourinary cancers and a particular focus on prostate cancer. He is an expert in the clinical management of patients with prostate cancer and other urological malignancies.

His research focuses on therapy development and clinical trial design for patients with prostate cancer. More specifically, he is interested in developing novel androgen-directed therapies as well as immunotherapies for men with recurrent or advanced prostate cancer. He also has an interest in biomarker development, specifically the clinical validation of the AR-V7 marker. He is currently the Principal Investigator of several phase II and III prostate cancer trials, and is an active member of the Prostate Cancer Clinical Trials Consortium (PCCTC) and the Eastern Cooperative Oncology Group (ECOG) as well as the NCI Prostate Cancer Task Force. He serves on the Editorial Board of several oncology journals, including the Journal of Clinical Oncology. He is the author of over 110 peer-reviewed articles, and several book chapters.

Lab

AR-V7 biomarker

Clinical Trial Keywords

Prostate Cancer

Clinical Trials

Phase II and III clinical trials in prostate cancer

Selected Publications

1. Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, Walsh PC, Eisenberger MA. The natural history of metastatic progression in men with PSA-recurrent prostate cancer after prostatectomy: long-term follow-up. BJU International 2012; 109: 32-39.

2. Antonarakis ES, Keizman D, Zhang Z, Gurel B, Lotan TL, Hicks JL, Fedor HL, Carducci MA, De Marzo AM, Eisenberger MA. An immunohistochemical signature comprising PTEN, MYC, and Ki67 predicts progression in prostate cancer patients receiving adjuvant docetaxel after prostatectomy. Cancer 2012; 118: 6063-6071.

3. Antonarakis ES, Heath EI, Smith D, Rathkopf D, Blackford A, Ajiboye AS, Zhao M, Mendonca J, Kachhap SK, Rudek MA, Carducci MA. Repurposing itraconazole as a treatment for prostate cancer: A non-comparative randomized phase II trial in men with metastatic castration-resistant prostate cancer. Oncologist 2013; 18: 163-173.

4. Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. New England Journal of Medicine 2014; 371: 1028-1038.

5. Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer. JAMA Oncology 2015; 1: 582-591.

Patents

Multiple novel androgen receptor variants as biomarkers and therapeutic targets for androgen-refractory human prostate cancer
Patent # C10305

Methods and compositions related to prostate cancer therapeutics
Patent # C13126

Activities & Honors

Honors

  • ASCO Young Investigator Award (2009), ASCO, 2009
  • PCF Young Investigator Award (2013), Prostate Cancer Foundation (PCF), 2013
  • SBUR/AUA Young Investogator Award (2015), Society for Basic Urologic Research of the AUA, 2015

Memberships

  • American Medical Association
  • American Society of Clinical Oncology
  • American Association for Cancer Research (AACR)
  • Eastern Cooperative Oncology Group (ECOG)
  • Prostate Cancer Clinical Trials Consortium (PCCTC)
  • Society for Basic Urologic Research (SBUR) of the AUA
Is this you? Edit Profile